+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gilead Sciences Inc: Coronavirus Disease 2019 (COVID-19) Company Impact

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


The Coronavirus (COVID-19) company impact report analyses how the pandemic will impact Gilead Science Inc. performance.
Historically, Gilead Focused on Small Molecules for Anti-Viral Therapies.
Gilead’s Pipeline is Most Active in Early Stages of Drug Development.
Remdesivir Is the Main Focus of Attention Against COVID-19.
Gilead Acquires Forty Seven Inc. as a Continuation of Strategy to Diversify Pipeline Portfolio into Oncology.

  • This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Gilead Science Incorporated. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Reasons to Buy
  • An overview of how Gilead Sciences Inc. will be affected by the COVID-19 pandemic.

Table of Contents

1 Executive Summary
2 Company Overview
2.1 Key Stats
2.2 SWOT Analysis
2.3 Sales Overview
3 Regional Breakout
3.1 COVID-19 Spread vs. Location of Gilead Sciences Inc. Trials
3.2 COVID-19 vs. Non-COVID-19 Trials
4 Reaction to COVID-19
4.1 Remdesivir Repurposed for COVID-19
4.2 Disrupted Clinical Trials
4.3 Deal Activity

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Gilead Sciences Inc.